Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PSC Biotech’s subsidiary PSC Investments has acquired a high potency sterile injectable facility from the Morgridge Institute for Research (MIR).
Subscribe to our email newsletter
Located in Wisconsin-Madison University Research Park, the 37,000ft2 sterile injectable fill finish facility will be a newly formed subsidiary of PSC Biotech, and will be named BioTechnique.
The facility was constructed in 2008 by Mentor Biologics and later conveyed to MIR.
PSC Investments managing director Raphi Hanessian said: "This was a great team effort from PSC Investments to help drive future growth potentials for PSC, and more importantly, help meet the high demand for cytotoxic and high potency fill-finish contract manufacturing services of sterile injectable products."
BioTechnique would provide specialized filling services for cytotoxic, high potency, biologic, and other sterile injectable drugs.
The injectable facility is designed to meet the highest safety levels for manufacturing personnel, minimize cross contamination, and be compliant with current Good Manufacturing Practices (cGMP) for sterile injectable manufacturing.
Expected to be customer ready for sterile liquid and lyophilization fill-finish production in 2015, BioTechnique would employ more than 100 technical professionals in Madison, Wisconsin, when fully operational.